Annual General Meeting of Active Biotech AB

The Annual General Meeting of Active Biotech was held on May 5, 2011.

In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.

In  accordance with  the Election  Committee's proposal,  the Board members Mats
Arnhög, Klas Kärre, Magnhild Sandberg and Peter Sjöstrand were re-elected. Peter
Hofvenstam,  Mef Nilbert  and Peter  Thelin were  elected as  Board members. The
Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board.

Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per end of September, 2011, as well as the Chairman
of the Board.

The Meeting approved the Board's proposal concerning guidelines for remuneration
to the President and other senior executives. The guidelines essentially conform
to the principles applied to date.

In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than six million new shares
and/or convertibles with the corresponding dilution effect, with or without pre-
emptive rights for the company's shareholders.

Finally,  pursuant to new  provisions in the  Swedish Companies Act, the meeting
approved  an amendment of  the Articles of  Association (Section 7), as follows:
Notice  of  general  meetings  shall  be  made through announcement in Post- och
Inrikes Tidningar and on the company's website. It shall be announced in Svenska
Dagbladet that a notice of a general meeting has been issued.

Lund, May 6, 2011

Active Biotech AB (publ)

Tomas Leanderson
President and CEO

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit  for more information.

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on May 6, 2011.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Annual General Meeting of Active Biotech AB:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE